Meredith Durkin Wolfe

Milwaukee

Director of Research at BioCentury

Featured in: Favicon

biocentury.com

Articles

I&I is the new hotness in East-to-West deals

1 week ago | biocentury.com | Meredith Durkin Wolfe

DATA GRAPHICS | Data ByteWhile oncology still dominates, a timeline of deals shows Western companies are increasingly turning to Asia for immunology and inflammation By Meredith Durkin Wolfe, Director of ResearchInnovation inI&I is emerging as a key driver of Asia-to-West dealmaking, as Western biotechs and pharmas expand their focus beyond oncology. Of 31 immunology and inflammation deals disclosed since 1Q23, 14 (45%) have been announced since the start of 4Q24.
Trading volume on Hong Kong’s biotech chapter is up in 2025

1 week ago | biocentury.com | Meredith Durkin Wolfe

DATA GRAPHICS | Data ByteChapter 18A stocks see increasing liquidity on Hong Kong stock exchange By Meredith Durkin Wolfe, Director of ResearchTrading volumes appear to be on the rise for stocks listed on Chapter 18A of the Stock Exchange of Hong Kong, reserved for pre-profit biopharma and medical device companies. As of Friday’s close, the average daily trading volume per company was 4.1 million so far in 2Q25, up from 3.3 million in 1Q25 and 2.4 million in 4Q24.
ODAC votes for Darzalex in smoldering multiple myeloma

2 weeks ago | biocentury.com | Meredith Durkin Wolfe

DATA GRAPHICS | Data ByteThree other products get negative committee outcomes By Meredith Durkin Wolfe, Director of ResearchThis week’s two-day Oncologic Drugs Advisory Committee meeting, which considered three label expansions and one new product, supported the risk-benefit profile of only one: Darzalex Faspro daratumumab/hyaluronidase to treat high-risk smoldering multiple myeloma.
Parsing biotech enterprise values

3 weeks ago | biocentury.com | Meredith Durkin Wolfe

DATA GRAPHICS | Data ByteBiopharmas mostly trading above cash, not deep in debt By Meredith Durkin Wolfe, Director of ResearchA snapshot of enterprise values for NASDAQ-listed biopharmas at year-end shows most companies trading above cash and lacking substantial debt, offering opportunities for good deals on acquisitions.
GSK’s liver asset play grows group of $1B upfront deals

3 weeks ago | biocentury.com | Meredith Durkin Wolfe

DATA GRAPHICS | Data ByteBoston Pharma-GSK deal is second over $1B up front this year, after Roche-Zealand By Meredith Durkin Wolfe, Director of ResearchWednesday’s deal in which GSK is acquiring Boston Pharma’s lead asset is the second deal this year with more than $1 billion in upfront cash for a single asset.
European biotechs favor discovery deals in Asia

3 weeks ago | biocentury.com | Meredith Durkin Wolfe

DATA GRAPHICS | BioCentury CommentaryNot seeking quick clinical data from licensing existing assets By Meredith Durkin Wolfe, Director of ResearchEuropean biotech companies are tapping Asian companies for their expertise in new therapeutics discovery, including antibody engineering, with two thirds of recent East-West deals by European companies devoted to identifying new products. In cross-border deals from Jan.
FDA approved three new drugs in April

1 month ago | biocentury.com | Meredith Durkin Wolfe

DATA GRAPHICS | Data ByteTotal CDER approvals stand at 10 so far this year, 50% less than at this time last year By Meredith Durkin Wolfe, Director of ResearchFDA approved just three NMEs in April, bringing the total for the first four months of the year to 10.
Moderna’s May PDUFA date to offer next signal on FDA vaccine policy

1 month ago | biocentury.com | Meredith Durkin Wolfe

DATA GRAPHICS | Data ByteA next-gen COVID vaccine among eight FDA decisions due in May By Meredith Durkin Wolfe, Director of ResearchAmong the eight PDUFA dates on FDA’s May calendar is a BLA for Moderna’s next-generation COVID-19 vaccine. The agency’s decision on the application will send a strong signal about whether any COVID vaccine can still win approval under the Trump administration. Moderna Therapeutics Inc.
CHMP recommends six orphan medicines

1 month ago | biocentury.com | Meredith Durkin Wolfe

DATA GRAPHICS | Data ByteSeven new products get positive opinions in April By Meredith Durkin Wolfe, Director of ResearchEMA’s CHMP recommended seven new drugs at its April meeting: five new orphan medicines, one new “orphan hybrid,” and a non-orphan product under standard review. An orphan hybrid is similar to FDA’s 505(b)(2) application for new formulations.
Another bleak day for stocks

2 months ago | biocentury.com | Meredith Durkin Wolfe

DATA GRAPHICS | Data ByteXBI and NBI continue to fall more than broader markets By Meredith Durkin Wolfe, Director of ResearchStocks fell again Tuesday, as markets continue to react to tariff policy. The XBI and NBI have lost 17% and 14% since last Friday, March 28, and 11% and 10% since tariffs were announced Wednesday. Their slide outpaces the broader markets, with the S&P500 down 11% since last Friday and 8% since Wednesday.